NEWARK, N.J., Dec. 13, 2010 /PRNewswire/ -- BioNeutral Group (OTC Bulletin Board: BONU), a specialty chemical technology-based life science company, was featured in the "Exec Access" column of the Bergen Record on Sunday, December 12, 2010. http://www.northjersey.com/news/121210_Firm_developing_formulas_to_clean_disinfect.html?page=all
The article, entitled, "Germs, Mold, Smelly Shoes are the Enemy," was written by veteran business reporter Joan Verdon, and includes background information on BioNeutral's Ygiene™ and Ogiene™ product lines, a preview of the momentum the company plans to build in the coming months, as well a Q&A with BioNeutral president and CEO Stephen Browand. Included in the Q&A with Browand are updates on the EPA regulatory approval process which BioNeutral has submitted its Ygiene™ product line for, further insights into the power and effectiveness of the company's Ogiene™ line, and an overview of the recent news that has helped the organization become one of the most disruptive companies in the cleaning and disinfecting markets.
"Exec Access" is a long-running weekly column, published by the Bergen Record, which is one of the largest and most respected daily publications in the tri-state area, with a circulation of nearly 200,000. The column features spotlights and profiles on fast-growing local businesses that are well-positioned to emerge as future leaders in their respective industries. In addition to the coverage in the Bergen Record, the story on BioNeutral is also expected to run in the Newark Star Ledger in the coming days, which is the largest-circulated newspaper in New Jersey.
This recognition continues to build on the momentum BioNeutral has achieved over the past several months . BioNeutral's Ygiene™ and Ogiene™ product lines have received acclaim in both commercial and consumer circles, alike, for their ability to kill dangerous microorganisms and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. Over the past month alone, BioNeutral has entered into an agreement with leading specialty pharmaceutical company DFB Pharmaceuticals, announced the successful results of a leading independent laboratory test for its Ygiene™ product line, and appointed industry veteran Dr. Andy Kielbania, to its Board of Directors.
"We are pleased by the recent momentum BioNeutral has built in advance of receiving EPA approval for our Ygiene™ product line," said Stephen Browand, CEO of BioNeutral Group. "The fact that we are now being recognized as an innovator in the technology and life sciences space by a leading business publication and media authority such as the Bergen Record validates our commitment to providing a new level of antimicrobial effectiveness to consumers and businesses, alike."
For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. For more information, see www.bioneutralgroup.com. AutoNeutral is a Registered trademark of BioNeutral Group, Inc.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.
SOURCE BioNeutral Group